Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6977649 | 0.93 | EPHX2 (0.50) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL2678496 | 0.92 | EPHX2 (0.52) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL11326316 | 0.92 | EPHX2 (0.52) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL7140606 | 0.89 | SMYD3 (0.50) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL20389672 | 0.86 | EPHX2 (0.48) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL31084448 | 0.85 | EPHX2 (0.52) | SMYD3USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL10866665 | 0.85 | HTR4 (0.44) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL31084480 | 0.85 | ALDH1A1 (0.46) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL14660151 | 0.84 | VCP (0.43) | SMYD3CYP1A2USP2ALDH1A1ALOX15 | |
| SCHEMBL31741885 | 0.84 | ALDH1A1 (0.45) | SMYD3CYP1A2USP2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-105017046-A | Preparation method of 4-cylopropylamine ethyl butyrate | SHANGHAI B&C CHEMICAL CO LTD | 2015-11-04 | — | — | CN | disclosed |
| CN-105017046-A | Preparation method of 4-cylopropylamine ethyl butyrate | SHANGHAI B&C CHEMICAL CO LTD | 2015-11-04 | — | — | CN | disclosed |
| US-20070276017-A1 | Thiadiazoline Derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-11-29 | — | — | US | disclosed |
| CN-1802361-A | M-stage kinesin inhibitor | KYOWA HAKKO KOGYO KK (JP) | 2006-07-12 | — | — | CN | disclosed |
| EP-1632484-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276017-A1 | Thiadiazoline Derivative | BRD7, NR3C2, NR5A2 | SMYD3 2213/4885CYP1A2 1024/4885USP2 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.